Wednesday, July 8, 2026

pharma · Asthma · Multiple Sclerosis · TEVA

Teva Pharma

Teva Biotech is a pharma organization headquartered in TEL AVIV, DE. It trades on NYSE under ticker TEVA. Primary therapeutic focus areas include Asthma, Multiple Sclerosis, Pain, Crohn's Disease, Seasonal Allergic Rhini

10 Dornierstr., Ulm, Donau, 89079, DE, TEL AVIV HQ
126 Employees
Public company Type
TEVA · NYSE Ticker
Company details
Clinical program

CD56-Enriched Donor Lymphocyte Infusion

Phase 1 · mab · Multiple Myeloma

CD56-Enriched Donor Lymphocyte Infusion for Multiple Myeloma is a Phase 1 program (mab) at Teva Pharma GmbH with 1 ClinicalTrials.gov record(s).

Internal code IIT2017-03-Merin-HaploBFR

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Teva Pharma GmbH
Phase
Phase 1
Modality
mab
Indication
Multiple Myeloma
Status
completed
Trials
1

Clinical trials